Please use this identifier to cite or link to this item:
Title: Studies of in vivo efficacy of flavonoid dimers in modulating p-glycoprotein (P-GP) mediated drug resistance
Authors: Yan, Sau Woon Clare
Advisors: Chow, Ming-cheung Larry (ABCT)
Keywords: Drug resistance in cancer cells
Issue Date: 2017
Publisher: The Hong Kong Polytechnic University
Abstract: A series of apigenin based novel flavonoid dimers were synthesized to tackle cancer MDR mediated by P-gp. Lead optimization through the introduction of an amine group within the PEG linker of parent compound 61 has led to the discovery of FD18. FD18 is more potent than 61, with an EC50 towards PTX decreased from 360 nM to 148nM and enhanced aqueous solubility. FD18, together with its derivatives, were characterized in vivo with the use of a newly established LCC6/MDR P-gp overexpressed human cancer nude mice model. This model is highly resistant to PTX treatment at 12 mg/kg (q.o.d. x 4 for 2 cycle), making it favorable to become an ideal testing platform. Subsequent treatment of these flavonoid compounds at 45 mg/kg together with PTX at 12 mg/kg (q.o.d. x 12) had demonstrated tumor inhibition effects, in which, FD18 was the most potent compound resulted in apromising %T-C of 54%. The safety profile of FD18 was also demonstrated through injections to healthy Balb/c mice and histopathological studies. No treated mice exerted toxicity deaths or weight loss >15% as well as cellular toxicities. DMPK study of FD18 has proposed one of its metabolite is an active P-gp inhibitor. This metabolite, namely FM04, has significantly increased in its aqueous solubility with a clogP value of 4.06 (clogP for FD18 is 7.07) and 50% more potent compared to FD18 in reversing PTX resistance from LCC6/MDR cells (EC50 = 70nM). It was compared with FD18 with essentially the same in inhibiting DOX transport and the role as a P-gp substrate. Finally, FM04 was better in in vivo P-gp modulating activity towards PTX treatment over FD18 with a %T-C of 57%. Together with its druggability as defined by the Lipinski Rule of 5, makes FM04 more favorable than FD18 as a drug candidate.
Description: xvii, 152 pages : color illustrations
PolyU Library Call No.: [THS] LG51 .H577P ABCT 2017 Yan
Rights: All rights reserved.
Appears in Collections:Thesis

Files in This Item:
File Description SizeFormat 
991021965753103411_link.htmFor PolyU Users167 BHTMLView/Open
991021965753103411_pira.pdfFor All Users (Non-printable)5.34 MBAdobe PDFView/Open
Show full item record
PIRA download icon_1.1View/Download Contents

Page view(s)

Last Week
Last month
Citations as of Oct 14, 2018


Citations as of Oct 14, 2018

Google ScholarTM


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.